IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Preliminary Phase I data clarified that BNZ-1 was well tolerated and inhibited IL-2 and IL-15 activity, leading to clinical improvement in participants with cutaneous T-cell lymphoma (CTCL) by rejuvenating anti-lymphoma immunity and reducing inflammatory responses (NCT03239392) (93).